Home >> Research Area >>Others>>Others>> Elacridar hydrochloride

Elacridar hydrochloride

BCRP and P-GP inhibitor CAS# 143851-98-3

Elacridar hydrochloride

Catalog No. BCC1547----Order now to get a substantial discount!

Product Name & Size Price Stock
Elacridar hydrochloride: 5mg $46 In Stock
Elacridar hydrochloride: 10mg Please Inquire In Stock
Elacridar hydrochloride: 20mg Please Inquire Please Inquire
Elacridar hydrochloride: 50mg Please Inquire Please Inquire
Elacridar hydrochloride: 100mg Please Inquire Please Inquire
Elacridar hydrochloride: 200mg Please Inquire Please Inquire
Elacridar hydrochloride: 500mg Please Inquire Please Inquire
Elacridar hydrochloride: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Elacridar hydrochloride

Number of papers citing our products

Chemical structure

Elacridar hydrochloride

3D structure

Chemical Properties of Elacridar hydrochloride

Cas No. 143851-98-3 SDF Download SDF
PubChem ID 170320 Appearance Powder
Formula C34H34ClN3O5 M.Wt 600.1
Type of Compound N/A Storage Desiccate at -20°C
Synonyms GF 120918
Solubility DMSO : 5 mg/mL (8.33 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
Chemical Name N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide;hydrochloride
SMILES COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC.Cl
Standard InChIKey IQOJZZHRYSSFJM-UHFFFAOYSA-N
Standard InChI InChI=1S/C34H33N3O5.ClH/c1-40-28-9-5-7-26-32(28)36-31-25(33(26)38)6-4-8-27(31)34(39)35-24-12-10-21(11-13-24)14-16-37-17-15-22-18-29(41-2)30(42-3)19-23(22)20-37;/h4-13,18-19H,14-17,20H2,1-3H3,(H,35,39)(H,36,38);1H
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Elacridar hydrochloride

DescriptionP-glycoprotein (P-gp/ABCG1) inhibitor. Blocks P-gp-mediated multidrug resistance (MDR) of the cytotoxic drugs doxorubicin and vincristine in CHRC5 cells. Also inhibits breast cancer resistance protein (BCRP/ABCG2). Orally active.

Elacridar hydrochloride Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Elacridar hydrochloride Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Elacridar hydrochloride

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.6664 mL 8.3319 mL 16.6639 mL 33.3278 mL 41.6597 mL
5 mM 0.3333 mL 1.6664 mL 3.3328 mL 6.6656 mL 8.3319 mL
10 mM 0.1666 mL 0.8332 mL 1.6664 mL 3.3328 mL 4.166 mL
50 mM 0.0333 mL 0.1666 mL 0.3333 mL 0.6666 mL 0.8332 mL
100 mM 0.0167 mL 0.0833 mL 0.1666 mL 0.3333 mL 0.4166 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Elacridar hydrochloride

Elacridar is an inhibitor of breast cancer resistance protein (BCRP) and P-glycoprotein (P-GP) that has been used to improve the brain distribution of drugs. Recent studies have revealed that elacridar could probably be the substrate of these multidrug transporters (MDTs) [2].
Recent studies had shown that elacridar and taxanes co-administrated orally could increase plasma concentrations of docetaxel (four-fold) and paclitaxel (10.7-fold) in mice. Co-administration of elacridar with taxanes and ritonavir could lead to a further increase in plasma concentrations of docetaxel (37.4-fold) and paclitaxel (31.9-fold). Besides, co-administration of elacridar with taxanes and ritonavir could potently increase taxanes concentration in the brain, but not increase the brain penetration of the taxanes [1].
Elacridar co-administrated orally with crizotinib has shown to increase the crizotinib concentrations in plasma and brain as well as increase the brain-to-plasma ratios of crizotinib, indicating that co-administration of crizotinib with elacridar could increase oral availability of crizotinib and delivery of crizotinib to the brain [2].
Apart from these, the uptake of elacridar at nanomolar doses in mouse brain was proved to be limited by Pgp- and Bcrp1-induced efflux at the blood - brain barrier. In vitro, Elacridar was indicated a low intracellular accumulation at nanomolar concentrations and a high intracellular accumulation at micromolar concentrations in Pgp- and Bcrp1-overexpressing cell lines [3].
References:
1.Hendrikx JJ1, Lagas JS2, Wagenaar E3, Rosing H2, Schellens JH4, Beijnen JH5, Schinkel AH3. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. Br J Cancer. 2014 May 27;110(11):2669-76. doi: 10.1038/bjc.2014.222. Epub 2014 Apr 29.
2.Chuan Tang S1, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94. doi: 10.1002/ijc.28475. Epub 2013 Oct 3.
3.Bankstahl JP1, Bankstahl M, Römermann K, Wanek T, Stanek J, Windhorst AD, Fedrowitz M, Erker T, Müller M, Löscher W, Langer O, Kuntner C.Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study. Drug Metab Dispos. 2013 Apr;41(4):754-62. doi: 10.1124/dmd.112.049148. Epub 2013 Jan 10.

Featured Products
New Products
 

References on Elacridar hydrochloride

Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies.[Pubmed:28010129]

Drug Dev Ind Pharm. 2017 Apr;43(4):584-594.

OBJECTIVE: A novel tablet formulation containing an amorphous solid dispersion (ASD) of Elacridar hydrochloride was developed with the purpose to resolve the drug's low solubility in water and to conduct proof-of-concept clinical studies. SIGNIFICANCE: Elacridar is highly demanded for proof-of-concept clinical trials that study the drug's suitability to boost brain penetration and bioavailability of numerous anticancer agents. Previously, clinical trials with elacridar were performed with a tablet containing Elacridar hydrochloride. However, this tablet formulation resulted in poor and unpredictable absorption which was caused by the low aqueous solubility of Elacridar hydrochloride. METHODS: Twenty four different ASDs were produced and dissolution was compared to crystalline Elacridar hydrochloride and a crystalline physical mixture. The formulation with highest dissolution was characterized for amorphicity. Subsequently, a tablet was developed and monitored for chemical/physical stability for 12 months at +15-25 degrees C, +2-8 degrees C and -20 degrees C. RESULTS: The ASD powder was composed of freeze dried Elacridar hydrochloride-povidone K30-sodium dodecyl sulfate (1:6:1, w/w/w), appeared fully amorphous and resulted in complete dissolution whereas crystalline Elacridar hydrochloride resulted in only 1% dissolution. The ASD tablets contained 25 mg Elacridar hydrochloride and were stable for at least 12 months at -20 degrees C. CONCLUSIONS: The ASD tablet was considered feasible for proof-of-concept clinical studies and is now used as such.

The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line.[Pubmed:9864431]

Oncol Rep. 1999 Jan-Feb;6(1):217-8.

GF120918, at 250 ng/ml, increased the sensitivity of a P-glycoprotein (P-gp)-mediated multidrug resistant (MDR) small cell lung cancer cell line (H69/LX4) to the P-gp substrates, paclitaxel, taxotere, vinblastine, vinorelbine, daunorubicin and etoposide to levels which were either greater (in the case of etoposide) or close to that of the parent cell line (H69/P). This was achieved in spite of the great variation in the levels of resistance of the MDR cell line for the various anti-cancer drugs tested. These data suggest that GF120918 is a potent antagonist of P-gp mediated multidrug resistance, even in the case of high levels of resistance, as was the case with paclitaxel and taxotere (2560 and 2215 fold more than the sensitive parent cell line respectively).

In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.[Pubmed:8402633]

Cancer Res. 1993 Oct 1;53(19):4595-602.

N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]- phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) has been selected from a chemical program aimed at identifying an optimized inhibitor of multidrug resistance (MDR). The potency of GF120918 is assessed by dose-dependent sensitization of CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine respectively: GF120918 fully reverses multidrug resistance at 0.05 to 0.1 microM and is half maximally active at 0.02 microM. The spectrum of drugs sensitized by GF120918 coincides with those having the classical MDR phenotype. In CHRC5 cells, 0.01-0.1 microM GF120918 enhances the uptake of [3H]daunorubicin and blocks the efflux from preloaded cells. It is also shown that GF120918 is still active several hours after being taken away from the culture medium showing that it is not, like verapamil, effluxed rapidly by P-glycoprotein. GF120918 effectively competes with [3H]azidopine for binding P-glycoprotein, pointing to this transport membrane protein as its likely site of action. After i.v. administration to mice, GF120918 penetrates thoroughly various organs that have a tissue level/blood level ratio above 10. It is eliminated from organs and blood with a half-time of approximately 2.7 h. It is well absorbed after p.o. administration. In mice implanted i.p. with the MDR P388/Dox tumor, a single i.v. or p.o. dose of GF120918 restores sensitivity of the tumor to a single i.p. dose (5 mg/kg) of doxorubicin administered 1 h later. A statistically significant effect is observed at 1 mg/kg GF120918 i.v. and maximal effect is reached at 5 mg/kg. Similarly, whereas neither drug alone is effective, GF120918 (10 mg/kg i.p.) associated with doxorubicin (5 mg/kg i.p.) inhibits the growth of the moderately MDR C26 tumor implanted s.c. as assessed by tumor size at day 19. GF120918 does not modify significantly the distribution or the elimination of doxorubicin in mice ruling out the possibility that the antitumor effects seen might be explained by pharmacokinetic interactions.

Description

Elacridar hydrochloride (GF120918A) is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules.

Keywords:

Elacridar hydrochloride,143851-98-3,GF 120918,Natural Products,Others, buy Elacridar hydrochloride , Elacridar hydrochloride supplier , purchase Elacridar hydrochloride , Elacridar hydrochloride cost , Elacridar hydrochloride manufacturer , order Elacridar hydrochloride , high purity Elacridar hydrochloride

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: